Alzheimer’s disease
Conditions
Interventions
Gold Standard:The patient has a clear complaint of cognitive decline. The diagnosis of Mild Cognitive Impairment (MCI) meets the NIA-AA 2011 diagnostic criteria. The diagnosis of Alzheimer's Disease (
Index test:The levels of p-tau217 and p-tau181 were measured in patients’ EDTA plasma.PCR-based assays were used to identify the most common alleles (e2, e3, e4).ApoE4 zygosity classification was dete
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.The samples are from the sample bank and have previously signed a broad informed consent form. 2.Participants were aged between 50 and 90 years; 3.PET results; 4.The subjects had undergone comprehensive clinical and neuropsychological assessments, including MMSE, MoCA, and CDR.
Exclusion criteria
Exclusion criteria: 1.Cognitive dysfunction or dementia caused by any non-AD diseases, including other neurodegenerative disorders (e.g., Lewy body dementia, frontotemporal dementia, Huntington's disease, Parkinson's disease, etc.), and non-neurodegenerative neurological conditions (e.g., vascular cognitive impairment or dementia, hydrocephalus, syphilis, encephalitis, hypoxic brain injury, traumatic brain injury, etc.); 2.cognitive dysfunction or dementia caused by non-neurological diseases, including endocrine disorders (e.g., hypothyroidism), hepatic insufficiency, pulmonary encephalopathy, dialysis encephalopathy, etc.; 3.Exclusion of toxic diseases (including alcoholism, drug dependence/abuse, delayed carbon monoxide encephalopathy, etc.); 4.Eliminate vitamin deficiencies (e.g., B12 deficiency, B1 deficiency, etc.) that may cause cognitive dysfunction or dementia; 5.Avoid testing for lipemia/hemolysis in samples;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The correlation p-tau217 and p-tau181 in the classification accuracy reflecting the status of ß-amyloid positive.;p-tau217 in the classification accuracy reflecting the status of ß-amyloid pathology.;p-tau181 in the classification accuracy reflecting the status of ß-amyloid pathology.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The correlation between plasma ApoE4 zygosity classification and APOE genotyping.; | — |
Countries
China
Contacts
Public ContactXia Yong
Peking University Shenzhen Hospital
Outcome results
None listed